rna
interfer
rnai
evolutionarili
conserv
mechan
silenc
gene
express
target
degrad
mrna
short
doublestrand
rna
known
small
interf
rna
sirna
incorpor
rnainduc
silenc
complex
direct
degrad
rna
contain
homolog
sequenc
rnai
shown
work
mammalian
cell
inhibit
viral
infect
control
tumor
cell
growth
vitro
recent
shown
intraven
inject
sirna
plasmid
express
sequenc
process
sirna
protect
mice
autoimmun
viral
hepat
rnai
could
provid
excit
new
therapeut
modal
treat
infect
cancer
neurodegen
diseas
ill
rna
interfer
rnai
ancient
defens
strategi
protect
plant
lower
invertebr
viral
infect
genom
damag
insert
genet
element
rnai
silenc
gene
express
sequencespecif
manner
cleav
mrna
contain
short
sequenc
nucleotid
length
close
homolog
target
sequenc
two
year
ago
sayda
elbashir
colleagu
spark
revolut
research
demonstr
rnai
oper
mammalian
cell
research
move
rapidli
appli
new
techniqu
understand
mammalian
gene
function
block
gene
express
vitro
studi
recent
provid
proof
principl
rnai
use
protect
mice
autoimmun
viral
hepat
review
discuss
promis
hurdl
har
rnai
human
therapi
clinic
situat
novel
therapi
might
first
appli
rnai
initi
describ
plant
caenorhabd
elegan
discov
doublestrand
rna
dsrna
much
potent
silenc
gene
express
either
sens
antisens
singlestrand
rna
ssrna
feed
worm
short
dsrna
homolog
sequenc
endogen
gene
caus
dramat
specif
reduct
gene
express
parallel
phenomena
cosuppress
endogen
gene
express
antivir
respons
plant
understood
due
posttranscript
gene
silenc
homolog
sequenc
past
year
becom
clear
similar
rnai
mechan
exist
plant
fungi
throughout
anim
kingdom
worm
fli
mammal
rnai
work
target
degrad
mrna
contain
homolog
case
ident
sequenc
introduc
short
oligonucleotid
fig
organ
mammal
silenc
amplifi
spread
target
neighbor
sequenc
via
process
involv
rnadepend
rna
polymeras
rnai
also
occur
fig
mechan
rna
interfer
doublestrand
ds
rna
process
dicer
atpdepend
process
produc
small
interf
rna
sirna
nucleotid
length
twonucleotid
overhang
end
short
hairpin
sh
rna
either
produc
endogen
express
viral
vector
also
process
dicer
sirna
atpdepend
helicas
requir
unwind
dsrna
allow
one
strand
bind
rnainduc
silenc
complex
risc
bind
antisens
rna
strand
activ
risc
cleav
mrna
contain
homolog
sequenc
addit
mechan
begin
describ
mammalian
cell
includ
work
chang
dna
methyl
chromatin
structur
induc
homolog
dsrna
other
work
mrna
degrad
via
translat
arrest
mrna
encod
close
homolog
sequenc
latter
mechan
use
endogen
microrna
mirna
might
particularli
import
regul
gene
express
develop
mirna
often
dsrna
imperfect
pair
plant
small
dsrna
complementari
strand
silenc
gene
gener
longer
dsrna
precursor
rna
nucleotid
length
mediat
rnai
wherea
longer
sequenc
nucleotid
length
implic
chromosom
silenc
process
dsrna
small
interf
rna
sirna
also
occur
drosophila
embryo
somat
cell
extract
endogen
gener
sirna
uniqu
dsrna
structur
strand
free
end
follow
base
pair
bp
pair
rna
twonucleotid
unpair
overhang
end
fig
search
enzym
process
longer
dsrna
sirna
focus
rnase
iii
famili
ribonucleas
whose
substrat
duplex
rna
whose
product
contain
end
class
evolutionarili
conserv
rnaseiiilik
enzym
contain
rna
helicas
activ
share
common
paz
piwiargonaut
zwill
domain
identifi
plant
divers
anim
speci
shown
process
dsrna
sirna
sirnagener
enzym
call
dicer
believ
act
dimer
rnai
machineri
might
also
essenti
cellular
function
exampl
delet
rnai
gene
fission
yeast
interfer
proper
segreg
chromosom
cell
divis
mainten
transcript
silenc
heterochromatin
particip
import
cellular
function
could
explain
known
exampl
natur
occur
anim
cell
incap
rnai
mechan
gene
silenc
induc
sirna
elucid
plant
worm
fli
begun
describ
mammalian
cell
initi
worm
rnai
shown
act
transcript
use
drosophila
embryo
lysat
phillip
sharp
colleagu
show
silenc
occur
via
destabil
mrna
suggest
dsrna
might
trigger
assembl
nucleas
complex
target
homolog
rna
degrad
current
model
suggest
duplex
sirna
first
unwound
use
atpdepend
helicas
one
strand
sirna
incorpor
larg
precursor
rnainduc
silenc
complex
risc
activ
risc
contain
singl
strand
rna
protein
homolog
product
argonaut
gene
famili
plant
c
elegan
drosophila
human
cell
uncharacter
factor
possibl
includ
unknown
endonucleas
respons
cleav
target
rna
rna
risc
complex
complementari
sequenc
target
rna
risc
complex
guid
rna
cleavag
middl
homolog
sequenc
mammalian
cell
introduct
dsrna
nucleotid
length
cytosol
activ
programm
global
gene
suppress
translat
arrest
activ
antivir
interferon
ifn
respons
long
dsrna
produc
life
cycl
virus
activ
dsrnadepend
protein
kinas
pkr
phosphoryl
achain
translat
elong
ainiti
factor
block
protein
synthesi
part
antivir
respons
activ
pkr
also
induc
ifn
product
activ
rnasel
degrad
rna
howev
sirna
nucleotid
length
effici
activ
pkr
ifn
product
henc
silenc
effect
exquisit
sequencespecif
although
rnai
import
antivir
defens
plant
current
evid
endogen
antivir
respons
mammal
use
rnai
howev
descript
rnai
mammal
recent
viral
inhibitor
rnai
describ
plant
anim
virus
would
surpris
virus
infect
mammal
produc
dsrna
intermedi
cytoplasm
devis
selfprotect
strategi
involv
inhibit
rnai
deliveri
express
sirna
mammalian
cell
use
silenc
wide
rang
gene
varieti
cell
type
studi
includ
proofofconcept
studi
silenc
report
gene
encod
green
fluoresc
protein
luciferas
studi
knockdown
gene
express
rapid
probe
gene
function
eg
encod
tubulin
dna
methyltransferas
lamin
cadherin
everincreas
number
report
probe
potenti
therapeut
use
exampl
rnai
shown
work
vitro
varieti
condit
cancer
silenc
bcr
abl
mutat
ra
human
papillomaviru
hpv
activ
transcript
factor
overexpress
protooncogen
autoimmun
diseas
silenc
fa
neurodegen
diseas
silenc
polyglutamin
sequenc
viral
infect
divers
replic
strategi
includ
respiratori
syncyti
viru
polioviru
hepat
b
hbv
hepat
c
hcv
hiv
hpv
influenza
even
gene
highli
transcrib
encod
lamin
tubulin
effect
silenc
howev
silenc
typic
incomplet
knockdown
rather
knockout
residu
gene
express
usual
least
per
cent
baselin
residu
gene
express
might
due
untransfect
cell
studi
studi
hiv
success
target
varieti
viral
gene
gag
rev
tat
well
viral
long
termin
repeat
host
cellular
receptor
rapidli
divid
transform
cell
silenc
transfect
sirna
last
less
review
week
transduc
macrophag
effect
silenc
least
three
week
least
target
gene
sirna
direct
hiv
block
hiv
product
given
within
week
infect
provid
sustain
inhibit
least
three
week
alreadi
infect
cell
ra
studi
possibl
target
mutat
ra
without
affect
unmut
ra
demonstr
exquisit
specif
rnai
therapeut
tool
howev
specif
could
pose
problem
therapeut
use
viral
infect
viral
escap
rnai
select
polioviru
alreadi
demonstr
although
resist
viru
alreadi
present
infect
inoculum
studi
one
way
around
viral
escap
target
one
gene
either
viru
target
host
viral
gene
moreov
rnai
mechan
toler
sequenc
mismatch
particularli
away
middl
cleavag
site
howev
rais
question
whether
nonspecif
silenc
partial
homolog
gene
present
problem
therapeut
use
fact
recent
vitro
studi
show
gene
incomplet
homolog
could
partial
silenc
effect
pronounc
higher
concentr
sirna
vector
deliveri
sirna
although
earli
studi
carri
transfect
chemic
synthes
sirna
recent
dsrna
express
stemloop
structur
encod
plasmid
retrovirus
lentivirus
vector
provid
mean
vivo
transduct
varieti
cell
includ
nondivid
cell
open
rang
possibl
therapeut
use
rnai
express
plasmid
gener
use
pol
iii
promot
express
sens
antisens
strand
separ
hairpin
structur
cell
dicer
process
short
hairpin
sh
rna
sens
strand
short
bp
loopantisens
strand
altern
antisens
strand
loop
sens
strand
effect
sirna
fig
sequenc
sirna
express
retrovir
lentivir
vector
shown
silenc
express
effect
varieti
primari
cell
includ
embryon
stem
es
cell
lymphocyt
macrophag
dendrit
cell
silenc
control
engin
induc
express
stem
loop
transfect
infect
es
cell
alreadi
use
produc
transgen
mice
constitut
induc
express
sirna
howev
infect
viral
vector
could
activ
antivir
inflammatori
respons
cell
interfer
intend
specif
particular
recent
studi
show
shrna
vector
encod
sirna
short
induc
ifn
respons
nonetheless
induc
express
gene
particip
ifn
respons
vivo
protect
hepat
use
rnai
although
studi
perform
vitro
often
cotransfect
protocol
might
mimic
natur
condit
recent
studi
demonstr
vivo
silenc
use
rnai
exampl
rapid
inject
duplex
sirna
larg
volum
ml
tail
vein
mice
effect
silenc
coinject
report
gene
express
howev
hydrodynam
inject
difficult
perform
reproduc
mice
requir
rapid
inject
mous
blood
volum
therefor
unlik
method
could
readili
scale
clinic
use
mous
experi
report
gene
effici
express
liver
organ
henc
silenc
also
demonstr
organ
hydrodynam
inject
duplex
sirna
direct
fa
effici
taken
mous
hepatocyt
effect
silenc
endogen
gene
express
ten
day
without
diminut
vivo
silenc
hepatocyt
began
wane
day
disappear
day
mice
silenc
fa
express
protect
hepat
destruct
death
two
model
autoimmun
hepat
fig
liver
fassirnatr
mice
control
mice
dramat
protect
vivo
treatment
concanavalin
cona
antifa
antibodi
former
case
inject
sirna
could
provid
protect
hepat
fibrosi
even
initi
second
six
weekli
inject
cona
antifa
sirna
protect
mice
death
induc
antifa
antibodi
control
mice
die
within
three
day
fassirnatr
mice
surviv
normal
liver
histolog
ten
day
later
mani
form
fulmin
hepat
irrespect
etiolog
viral
autoimmun
transplant
reject
mediat
engag
fa
receptor
hepatocyt
henc
silenc
fa
express
distal
mediat
apoptosi
could
use
strategi
treat
hepat
gener
fact
recent
studi
silenc
activ
downstream
fasreceptor
engag
show
protect
autoimmun
adenovir
hepat
addit
cotransfect
hydrodynam
inject
mice
hbv
plasmid
plasmid
express
shrna
target
hbv
sequenc
process
sirna
within
cell
reduc
hbv
product
infect
liver
cell
therefor
potenti
rnai
treat
hepat
target
apoptot
viral
gene
alreadi
demonstr
vivo
move
sirna
therapi
mice
peopl
although
hydrodynam
deliveri
doublestrand
sirna
induc
effect
silenc
state
liver
mice
unlik
strategi
scale
human
introduct
duplex
sirna
requir
transient
gener
high
local
intravascular
pressur
mice
sirna
inject
bolu
tail
vein
volum
mous
circul
blood
volum
although
method
could
presum
adapt
transduc
select
tissu
via
region
catheter
deliv
sirna
preoper
transplant
organ
unlik
possibl
adapt
protocol
safe
system
human
treatment
although
dsrna
resist
rnase
intraven
halflif
unmodifi
duplex
sirna
short
small
molecul
degrad
endogen
nucleas
quickli
filter
kidney
therefor
duplex
sirna
need
chemic
modifi
use
inject
drug
use
rnai
therapi
might
enhanc
target
deliveri
particular
cell
virusinfect
cell
tumor
tissu
prevent
unwant
effect
normal
host
tissu
target
deliveri
achiev
either
local
administr
skin
mucosa
eye
inject
via
catheter
vascular
suppli
particular
organ
principl
chemic
modifi
sirna
could
also
coval
link
ligand
cellsurfac
receptor
enabl
deliveri
cell
bear
receptor
howev
target
deliveri
duplex
sirna
induc
silenc
state
remain
demonstr
similarli
viral
vector
could
theoret
target
incorpor
envelop
gene
specif
cell
deliveri
deliveri
strategi
therapi
sever
strategi
develop
stabil
antisens
oligonucleotid
ribozym
includ
cap
end
modifi
ribos
sugar
substitut
phosphorothio
stabil
sirna
without
toxic
might
jeopard
abil
target
mrna
degrad
moreov
modif
sens
strand
particularli
end
thought
interfer
gene
silenc
coval
coupl
antibodi
ligand
cellsurfac
receptor
end
sens
strand
provid
method
target
sirna
specif
cell
tissu
therapeut
interest
coval
even
noncoval
linkag
basic
peptid
deliv
oligonucleotid
cell
incorpor
sirna
liposom
could
also
provid
univers
deliveri
mechan
insid
cell
duplex
sirna
expect
induc
silenc
state
last
week
least
cell
continu
undergo
cell
divis
could
ideal
therapeut
window
mani
chronic
diseas
long
enough
requir
treatment
everi
week
monthli
short
enough
rais
concern
longterm
toxic
perman
silenc
gene
howev
introduc
oligonucleotid
nondivid
cell
lymphocyt
hematopoiet
stem
cell
notori
difficult
could
requir
special
strategi
deliveri
via
viral
vector
addit
deliv
sirna
drug
also
consider
interest
deliv
sirna
express
plasmid
viral
vector
approach
benefit
drawback
gene
therapi
benefit
potenti
lifelong
express
sirna
result
stabl
integr
plasmid
genom
dna
abil
target
nondivid
cell
stem
cell
lymphocyt
neuron
disadvantag
low
proport
transduc
cell
rapid
loss
gene
express
use
current
gene
therapi
method
danger
oncogen
transform
insert
mutagenesi
danger
unanticip
toxic
longterm
silenc
human
gene
gene
potenti
target
silenc
rnai
henc
therapeut
possibl
endless
fact
coupl
specif
potenc
silenc
sirna
activ
molar
basi
antisens
oligonucleotid
caus
worker
tout
sirna
potenti
biggest
revolut
therapeut
sinc
develop
specif
antibodi
moreov
sirna
like
much
cheaper
manufactur
administ
antibodi
therapi
therapeut
strategi
sirna
base
silenc
either
nonessenti
wildtyp
gene
link
diseas
silenc
mutat
gene
mutat
caus
diseas
abl
deliv
sirna
specif
cellular
target
broaden
list
gene
silenc
without
induc
toxic
target
mutat
sequenc
costli
difficult
execut
therapi
need
custom
patient
determin
individu
gene
mutat
synthes
homolog
sirna
vitro
translat
studi
rnai
carri
date
focus
mainli
viral
infect
cancer
like
area
earli
therapeut
effort
virus
infecti
agent
although
rnai
ancient
antivir
defens
plant
unknown
whether
play
role
natur
defens
mammalian
cell
virus
nonetheless
seem
logic
tri
har
mechan
control
viral
infect
particularli
given
silenc
viral
gene
unlik
advers
consequ
host
search
sequenc
target
lack
homolog
human
gene
use
rnai
could
use
treat
acut
viral
infect
influenza
sever
acut
respiratori
syndrom
caus
major
morbid
death
treat
chronic
infect
eventu
progress
chronic
infect
caus
morbid
throughout
world
hbv
hepat
c
hcv
hiv
intracellular
pathogen
mycobacterium
tuberculosi
might
also
amen
rnai
like
among
first
therapeut
target
investig
attract
viral
target
viral
gene
essenti
replic
sequenc
rel
conserv
viral
strain
mutat
would
result
lessrobust
infecti
agent
host
gene
requir
viral
entri
play
essenti
role
viral
life
cycl
also
potenti
good
target
provid
requir
surviv
cell
rna
virus
hiv
hcv
region
viral
genom
includ
nontranscrib
region
regulatori
gene
also
target
possibl
rnai
machineri
could
limit
factor
mammalian
cell
restrict
number
sequenc
success
target
time
within
cell
nonetheless
minim
risk
viral
escap
mutat
undermin
rnai
simultan
target
sever
viral
andor
host
gene
import
differ
stage
viral
life
cycl
might
use
strategi
moreov
synergist
enhanc
viral
suppress
demonstr
target
one
gene
although
bacteria
amen
silenc
sirna
mainli
replic
outsid
cell
lack
rnai
machineri
might
possibl
reduc
morbid
mortal
lifethreaten
bacteri
infect
silenc
gene
involv
aspect
stereotyp
host
immun
respons
lead
advers
consequ
exampl
reduc
express
proinflammatori
cytokin
tumor
necrosi
factor
tnfa
might
lessen
risk
septic
shock
without
jeopard
develop
protect
immun
treatment
would
complement
antibiot
therapi
could
institut
even
infecti
agent
identifi
fact
recent
studi
mice
sepsi
induc
treatment
lipopolysaccharid
block
inject
liposom
contain
duplex
sirna
target
tnfa
sever
vitro
studi
alreadi
demonstr
potenti
use
rnai
treat
cancer
gene
target
shown
slow
tumor
growth
includ
product
gene
characterist
mutat
gener
specif
cancer
either
transloc
bcr
abl
chronic
myeloid
leukemia
point
mutat
ra
produc
constitut
activ
oncogen
oncogen
potenti
ra
mutat
atyp
chang
singl
amino
acid
render
molecul
constitut
activ
oncogen
henc
small
number
differ
mutat
seen
repeatedli
mani
cancer
result
target
ra
would
need
requir
custom
therapi
tumor
howev
although
type
cancer
mutat
transloc
occur
fairli
welldefin
locat
nonetheless
divers
target
without
sequenc
mutat
gene
tumor
need
treat
howev
target
downstream
sequenc
transloc
gene
abl
sequenc
bcr
abl
might
effect
therapi
particularli
tumor
cell
could
transfect
select
vivo
howev
sever
gene
mutat
cancer
overexpress
make
cell
resist
nativ
immun
treatment
normal
senesc
mani
gene
overexpress
wide
array
tumor
attract
target
silenc
includ
gene
encod
multidrugresist
protein
mdr
pump
chemotherapeut
drug
tumor
telomeras
overcom
chromosom
shorten
occur
cell
divis
make
cell
resist
caspasemedi
apoptosi
potenti
target
rnai
growth
factor
growth
factor
receptor
oncogen
role
specif
tumor
exampl
includ
multipl
myeloma
breast
cancer
possibl
target
viral
oncogen
hpv
gene
cervic
cancer
synthesi
angiogen
factor
vascular
endothelia
tumor
could
also
silenc
fact
list
possibl
cancer
target
rnai
includ
gene
recent
target
use
convent
drug
antibodi
antisens
oligonucleotid
make
rnai
attract
altern
anticip
high
degre
specif
effect
rare
seen
smallmolecul
inhibitor
possibl
hit
multipl
gene
target
time
also
greatli
increas
chanc
success
success
rnai
therapi
cancer
indic
depend
larg
part
stabl
possibl
tumorspecif
deliveri
deliveri
method
need
tailormad
type
cancer
exampl
cervic
cancer
local
instil
stabil
duplex
oligonucleotid
could
requir
howev
dissemin
hematolog
tumor
target
via
cellspecif
receptor
might
work
better
particularli
target
gene
essenti
function
nontransform
cell
anoth
class
diseas
defi
convent
approach
might
amen
rnai
neurodegen
diseas
caus
overexpress
mutat
gene
protein
contain
long
polyglutamin
stretch
target
express
mutat
allel
polyglutamin
sequenc
could
slow
prevent
onset
neuron
cell
death
interf
express
apoptot
gene
select
nervou
system
could
effect
known
review
whether
sirna
cross
blood
brain
barrier
limit
factor
elucid
best
select
deliveri
strategi
target
neuron
might
requir
local
inject
cerebrospin
fluid
modifi
sirna
retrovirus
lentivirus
effici
infect
nerv
cell
therapeut
possibl
endless
almost
diseas
express
overexpress
nativ
mutat
gene
caus
diseas
potenti
target
provid
low
express
wildtyp
toxic
initi
clinic
studi
inevit
chosen
treat
ailment
afflict
larg
number
peopl
current
avail
treatment
suboptim
expens
treatment
potenti
sourc
toxic
sirna
appear
high
specif
like
small
molecul
sequencespecif
nonspecif
impedi
therapeut
applic
could
aris
deliveri
issu
solv
target
deliveri
possibl
reduc
likelihood
toxic
side
effect
also
expect
dosedepend
could
mitig
administ
less
sirna
adjust
halflif
chemic
modif
use
lesspot
express
system
vector
deliveri
possibl
side
effect
includ
unintend
silenc
partial
homolog
gene
either
mrna
degrad
suppress
translat
induct
global
gene
suppress
activ
ifn
respons
especi
shrna
express
viral
vector
anoth
potenti
problem
caus
therapeut
introduct
sirna
could
inhibit
function
endogen
mirna
compet
rnai
machineri
rnai
provid
excit
new
therapeut
tool
wide
array
potenti
diseas
target
specif
effect
gene
silenc
rnai
promis
therapi
high
therapeut
index
devis
strategi
deliv
sirna
cell
stabl
cellspecif
manner
major
impedi
present
given
rapid
pace
field
impress
demonstr
efficaci
vitro
mice
human
pilot
studi
provid
proof
principl
therapeut
use
like
undertaken
within
next
year
